Metabolism Disorder TRIZ Cases

Administering a ketogenic composition with beta-hydroxybutyrate increases ketone body concentrations to address metabolic dysfunction in Kabuki Syndrome.

A TAT peptide variant replaces internal residues with hydrophobic aliphatic amino carboxylic acid or polyethylene glycol to boost water solubility and synthesis yield.

Tubulin polymerization inhibitors raise CD184 surface levels, resolving the difficulty in regulating migration for effective transplantation.

Modified acid alpha glucosidase uses phosphorylated mannose to improve cellular uptake, reducing glycogen levels in tissues while lowering dosing frequency.

Biodegradable polymers swell in the stomach to lower gastric volume while degrading in the intestine, preventing small bowel obstruction.

Alcohol extraction and non-ionic resin adsorption isolate 1,25-dihydroxyvitamin D3 glycosides from Solanum glaucophyllum.

Tacr2 peptide agonists activate brown adipose tissue to increase oxygen consumption and glucose uptake.

Combining this Fc-linked insulin with an exendin-4 conjugate reduces hypoglycemia risk, weight gain, and nausea while increasing pancreatic beta cell mass.

A non-dairy solid dosage form combines lactase enzyme with dried Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus thermophilus.

A liquid aqueous pharmaceutical formulation uses histidine buffer, proline, sorbitol, and polysorbate to maintain IL-36 antibody integrity.

Albiglutide fusion protein extends serum half-life via albumin conjugation to enable weekly subcutaneous dosing.

Combining a self-microemulsifying drug delivery system with an antacid bolus raises gastric pH to prevent acid-mediated degradation of hydrophilic drugs.

Transverse uncoupling prevents accidental cannula withdrawal while enabling flexible device positioning.

Lipolytic enzymes liberate free fatty acids that bind calcium, preventing complex formation and boosting phytase activity for improved phosphate absorption.

Lactobacillus delbrueckii strains modulate immune pathways to lower IgE, addressing side effects of conventional antihistamine treatments.

Dihydroberberine improves glucose tolerance while reducing gastrointestinal side effects.

A nitrosylated peptide mimics hepatic insulin sensitizing substance to stimulate glucose uptake in skeletal muscle and heart tissues.

Co-agonist peptides combine amino acid substitutions and fatty acid conjugations to extend serum half-lives beyond one day.

Human beta-globin IVS2 intron in rAAV vectors boosts transgene expression, lowering vector doses to minimize immune responses.

A defined culture protocol differentiates pluripotent stem cells into pancreatic endocrine lineages using specific growth factors and glucose concentrations.

A low-temperature water extract of hibiscus manihot inhibits lipid accumulation by modulating enzyme expression.

Conjugate compounds deliver CRISPR-Cas9 ribonucleoproteins to hepatocytes via ASGPR receptors, resolving endosomal escape and safety risks.

Benzyl alcohol prevents self-aggregation and precipitation of the peptide, ensuring therapeutic effectiveness for diabetes treatment.

Buffered dual-receptor agonist formulation reduces gastrointestinal side effects while maintaining blood glucose control.

Lipid nanoparticles deliver mRNA encoding methylmalonyl-CoA mutase to restore enzyme activity.

Galacto-oligosaccharide composition stimulates Propionibacterium growth in the gut to produce propionate, bypassing upper GI absorption barriers.

Balanced dual agonist peptides reduce gastrointestinal adverse events while controlling blood glucose levels.

Sirt7 gene therapy reverses aging features and extends lifespan by 75% in progeria mice through targeted endothelial repair.

CTPI compounds inhibit the SLC25A1 mitochondrial carrier to overcome therapy resistance driven by aerobic glycolysis reliance.

Sotagliflozin improves cardiorenal health while minimizing diabetic ketoacidosis risk through patient selection.

A rosemary extract composition with ursolic acid inhibits pancreatic lipase activity to modulate body weight.

SGLT2 inhibitor dapagliflozin reduces Type 2 diabetes risk in prediabetic patients with elevated HbA1c or fasting glucose levels.

Concurrent thymus and parathyroid tissue implantation corrects immunologic and metabolic deficiencies, eliminating calcium supplementation needs.

Beta-lactam compounds manage glucose metabolism disorders with prolonged therapeutic effects lasting weeks after single administration.

Recombinant yeast produces myosin and actin filaments to form synthetic meat, reducing water consumption and land use.

STRO-1+ cells regenerate pancreatic beta cells to address underlying dysfunction beyond simple symptom management.

ProAlgaZyme microbial fermentation product downregulates CETP while upregulating ABCA1 and ApoA1 to lower LDL and raise HDL without statin side effects.

Covalent conjugation of exendin-4 with a polymer and Fc region extends blood circulation time.

Lactobacillus probiotics modulate gut microbiota to restore GLP-1 receptor expression, addressing impaired sensitivity in type 2 diabetes patients.

NHE3-binding compounds reduce serum phosphate levels by blocking gastrointestinal uptake, avoiding hypercalcemia risks associated with calcium-based binders.

ROR1-positive mesenchymal stem cells exhibit increased migratory capacity and mitochondrial transfer capabilities.

Isoelectric focusing separates Streptomyces fradiae proteases to remove biological impurities, ensuring precise therapeutic effects and improved growth.

Small molecule allosteric modulators bind to the parathyroid hormone type 1 receptor to negatively regulate signaling pathways.

Administering a composition containing wedelolactone, luteolin, and apigenin to lower serum triglyceride levels.

Tenacibaculum sp. fermentation lowers uric acid while avoiding long culturing durations and contamination risks.

Attaching chorionic gonadotropin peptides to growth hormone extends half-life, reducing dosing frequency and improving patient comfort.